Sam E. Moussa

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.4K citations · Full text

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 733 citations

Metabolic Associated Steatohepatitis, Hepatology, Nonalcoholic Fatty Liver Disease +10

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Stephen A. Harrison, Rebecca Taub, Guy Neff et al. · Nature Medicine · 2023 · 348 citations · Full text

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Stephen A. Harrison, Guy Neff, Cynthia D. Guy et al. · Gastroenterology · 2020 · 257 citations · Full text

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Stephen A. Harrison, Mustafa R. Bashir, Sam E. Moussa et al. · Hepatology Communications · 2021 · 176 citations · Full text